How to overcome endocrine resistance in early and metastatic breast cancer

Abstract

According to St. Gallen Consensus, endocrine responsive breast cancer is defined by positive steroidal receptors (ER= estrogen receptor and PR= Progesterone Receptor). ER/PR and HER2 are the most important biomarkers in decisionmaking about adjuvant and palliative treatment options. Available data suggest, that the higher the expression of ER and PR, the better the outcome for patients with early and advanced breast cancers.